Study supports chemotherapy option that reduces side effects for people with gastrointestinal cancers

Research published online by the Journal of the National Comprehensive Cancer Network (JNCCN) finds that for many commonly-used treatment regimens targeting metastatic gastrointestinal (GI) cancers, such as FOLFOX, FOLFIRI, or FOLFIRINOX, it is possible to administer 5-FU solely through continuous infusion, minus the bolus (quick-delivery via intravenous push) component, without negatively affecting patient outcomes.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup